Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations
Carregando...
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
BIPOLAR DISORDERS, v.18, n.8, p.692-695, 2016
Resumo
Objectives: The putative neuroprotective effects of lithium treatment rely on the fact that it modulates several homeostatic mechanisms involved in the neurotrophic response, autophagy, oxidative stress, inflammation, and mitochondrial function. Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression. The aim of this study was to evaluate the effects of subtherapeutic and therapeutic concentrations of chronic lithium treatment on brain-derived neurotrophic factor (BDNF) synthesis and secretion. Methods: Primary cultures of cortical and hippocampal neurons were treated with different subtherapeutic (0.02 and 0.2 mM) and therapeutic (2 mM) concentrations of chronic lithium treatment in cortical and hippocampal cell culture. Results: Lithium treatment increased the intracellular protein expression of cortical neurons (10% at 0.02 mM) and hippocampal neurons (28% and 14% at 0.02 mM and 0.2 mM, respectively). Extracellular BDNF of cortical neurons increased 30% and 428% at 0.02 and 0.2 mM, respectively and in hippocampal neurons increased 44% at 0.02 mM. Conclusion: The present study indicates that chronic, low-dose lithium treatment -up-regulates BDNF production in primary neuronal cell culture.
Palavras-chave
BDNF, chronic lithium treatment, cortical neurons, hippocampal neurons, low-dose lithium treatment
Referências
- Bachmann RF, 2005, MOL NEUROBIOL, V32, P173, DOI 10.1385/MN:32:2:173
- Conner JM, 1997, J NEUROSCI, V17, P2295
- Damri O, 2015, EUR NEUROPSYCHOPHARM, V25, P425, DOI 10.1016/j.euroneuro.2014.06.012
- De-Paula VD, 2015, MOLECULES, V20, P19878, DOI 10.3390/molecules201119663
- De-Paula VJ, 2016, CURR ALZHEIMER RES, V13, P848, DOI 10.2174/1567205013666160219112612
- Dwivedi T, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00457
- Emamghoreishi M, 2015, IRAN J BASIC MED SCI, V18, P240
- Forlenza OV, 2014, ACS CHEM NEUROSCI, V5, P443, DOI 10.1021/cn5000309
- Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
- Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871
- [Громова О.А. Gromova O.A.], 2015, [Журнал неврологии и психиатрии им. C.C. Корсакова, Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova], V115, P65
- Guttuso T, 2016, J NEUROL SCI, V368, P221, DOI 10.1016/j.jns.2016.07.027
- Hashimoto R, 2002, NEUROPHARMACOLOGY, V43, P1173, DOI 10.1016/S0028-3908(02)00217-4
- Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
- Jiao Y, 2014, BIOMED RES INT, V2014
- Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9
- Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8
- Machado-Vieira R, 2009, BIPOLAR DISORD, V11, P92, DOI 10.1111/j.1399-5618.2009.00714.x
- Mariga A, 2016, NEUROBIOL DIS, V61, P353
- McAllister AK, 1999, P NATL ACAD SCI USA, V96, P13600, DOI 10.1073/pnas.96.24.13600
- Motoi Y, 2014, ACS CHEM NEUROSCI, V5, P434, DOI 10.1021/cn500056q
- Nunes MA, 2015, PLOS ONE, V25
- Park SW, 2015, BIPOLAR DISORD, V17, P278, DOI 10.1111/bdi.12262
- Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
- Schwieger J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133680
- Smith ED, 2014, J BIOL CHEM, V289, P20615, DOI 10.1074/jbc.M114.568659
- Solntseva EI, 2016, NEUROCHEM INT, V94, P67, DOI 10.1016/j.neuint.2016.02.007
- Su HX, 2009, J NEUROCHEM, V108, P1385, DOI 10.1111/j.1471-4159.2009.05902.x
- Toker L, 2014, ACS CHEM NEUROSCI, V5, P411, DOI 10.1021/cn5001149
- Vo TM, 2015, ANN CLIN PSYCHIATRY, V27, P49